Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Blacks Fare Better After This Type of Transplant

Biol Blood Marrow Transplant.; ePub 2018 Jan 25; Solomon, et al

Black patients appear to experience less disease relapse than whites following post-transplant cyclophosphamide-based haploidentical donor transplantation (PTCy-HIDT), according to an analysis involving 203 individuals. Participants were a median age of 53 years and comprised blacks (n=80) and whites (n=123) who underwent first PTCy-HIDT for hematologic malignancies at a single center. Peripheral blood stem cell was used in two-thirds of patients, and 4 in every 10 received myeloablative conditioning. Among the results:

  • 3-year overall survival, disease-free survival, and relapse rates in blacks were 72%, 65%, and 25%, respectively.
  • These rates in whites were 50%, 45%, and 39%, respectively.
  • Non-relapse mortality, acute graft-versus-host disease (GVHD), and moderate-to-severe chronic GVHD rates were similar in both groups.
  • Improved survival was seen in all black patient subgroups.
  • Blacks were 53% more likely than whites to experience better overall survival.
  • They were 51% more likely to experience better disease-free survival.

Citation:

Solomon S, Zhang X, Holland H, Morris L, Solh M, Bashey A. Superior survival of black versus white patients following post-transplant cyclophosphamide-based haploidentical transplantation for adults with hematologic malignancy. [Published online ahead of print January 25, 2018]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.01.024.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Myelodysplastic Syndrome

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

JAK1/2 inhibitors tied to increased B-cell lymphoma risk, Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126 https://doi.org/10.1016/S2352-3026(18)30016-4

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al